Dr. Liu is an experienced biotechnologist, virologist, biochemist and serial entrepreneur. Prior to Avirmax, Dr. Liu held an executive position, chief scientist and global head of Pathogen Safety of Bayer Pharmaceuticals. Dr. Liu was a founder and the president of Abmaxis Inc. which was dedicated to develop Abmaxis in Silico IMmunization (ASIM TM ), an integrated technology of antibody engineering, phage display and production. Abmaxis Inc. was acquired by Merck in 2006. Dr. Liu was the group leader of Genentech BSL-3 Virology Research Lab (1996-2000). In his scientific career, he developed bioprocess technologies to prevent commercial scale bioreactors from virus contamination and secured virus safety for biotherapeutics. He discovered and characterized a new virus, rabbit hemorrhagic disease virus (RHDV), the rabbit calicivirus in 1984. He developed an inactivated RHDV vaccine and several fast diagnostic methods effectively used for controlling and preventing the disease. During his past 25 years of biotechnological career, he played key roles in innovation, development, tech transfer and manufacturing support and regulatory submission for approvals at various development stages of 33 biologics including AAV mediated GT products, among those 10 are widely used biologics. Dr. Liu received his Ph.D. in Biochemistry from Kansas State University (1990-93) and his post-doctoral training with Dr. Arthur Kornberg, Stanford University (1994-1996). Dr. Liu is a member of Parental Drug Association (PDA), World Federation of Hemophilia (WFH) and an advisor of Bioengineering Department of Santa Clara University (Santa Clara, CA) and Techcode (Mountain View, CA).